Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease

doi:10.3748/wjg.14.5584

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 36

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4555)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

472

HTML

3892

Figures (1-1)

Tables (1-5)

105

Sum=4555

Sep 28, 2008 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (103)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Sep 28, 2008; 14(36): 5584-5589
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5584

Open in New Tab Full Size Figure Download Figure

Figure 1 FC levels (box displays median, 25-75th percentile and lines 10-90th percentile with dots displaying outliers), and treatment outcome in terms of complete and incomplete response in patients with UC and CD treated for 8 wk.

Citation: Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584-5589
URL: https://www.wjgnet.com/1007-9327/full/v14/i36/5584.htm
DOI: https://dx.doi.org/10.3748/wjg.14.5584